Why Indian Generics Power Global Health: The Numbers Behind the 'Pharmacy of the World'
India supplies 20% of global generic volume and 60% of world vaccine production. The industrial history and quality evolution behind the statistics.
One in five generic medicines consumed anywhere on earth is manufactured in India. The country supplies about 60% of global vaccine volume, roughly half of Africa's generic medicines, and a substantial share of the antiretrovirals that transformed the HIV epidemic. 'Pharmacy of the world' is marketing language that happens to be statistically accurate.
How the capability was built
India's 1970 Patents Act recognized process patents rather than product patents, allowing Indian firms to legally re-engineer manufacturing routes for existing molecules. Three decades of that competition produced something more durable than any patent regime: the world's deepest bench of process chemists and the lowest sustainable cost base for quality-assured formulation manufacturing.
When India joined TRIPS-compliant product patents in 2005, the industry had already pivoted to regulated-market generics. Today India hosts more US FDA-approved facilities than any country outside the United States, alongside hundreds of WHO-GMP plants serving emerging markets.
The quality conversation, honestly
The industry's scale means its failures make headlines, and buyers should take them seriously rather than defensively. The practical lesson is not that Indian sourcing is risky — it is that supplier selection matters enormously in a market of 3,000+ manufacturers spanning the full quality spectrum. Facility audits, batch documentation and stability data separate the exporters worth partnering with.
For global health systems facing medicine budgets that never match medicine needs, the Indian generic industry remains the most consequential affordability engine in existence. Buying from it well is a skill — and a competitive advantage for those who build it.